Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press11910.17650/1726-9776-2013-9-3-55-58PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫTHE LONG-TERM ONCOLOGICAL RESULTS OF RADICAL PROSTATECTOMY IN PATIENTS WITH A MAXIMUM FOLLOW-UP OF UP TO 15 YEARS, WHO MEET THE ERSPC (PRIAS) CRITERIA FOR ACTIVE SURVEILLANCEОТДАЛЕННЫЕ ОНКОЛОГИЧЕСКИЕ РЕЗУЛЬТАТЫ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ У ПАЦИЕНТОВ С МАКСИМАЛЬНЫМ СРОКОМ НАБЛЮДЕНИЯ ДО 15 ЛЕТ, СООТВЕТСТВУЮЩИХ КРИТЕРИЯМ АКТИВНОГО НАБЛЮДЕНИЯ ERSPC (PRIAS)VelievE. I.ВелиевЕ. И.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruLoranO. B.ЛоранО. Б.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruSokolovE. A.СоколовЕ. А.
Russian Federation

Department of Urology and Surgical Andrology

кафедра урологии и хирургической андрологии

rmapo@yandex.ruRussian Medical Academy of Postgraduate Education, Ministry of Health of the Russian, MoscowГБОУ ДПО РМАПО МЗ РФ, Москва300920139355582707201427072014https://oncourology.abvpress.ru/oncur/article/view/119

No consensus on how to select patients is one of the factors restricting the wide acceptance of active surveillance (AS). The frequency of unfavorable histological findings and long-term overall and relapse-free survival rates were studied in 152 patients who met the ERSPC [European Randomized Study of Screening for Prostate Cancer] (PRIAS) criteria for AS and had undergone retropubic prostatectomy (RPE) in the period 1997 to 2010. Negative histological characteristics were found in more than 10 % of the patients, with the median postoperative followup of 67 months biochemical recurrence developed in 3 (2 %) patients. Five- and ten-year relapse-free survival rates were 97 and 88.2 %, respectively. Histological and long-term oncological results after RPE are suboptimal in the patients meeting the PRIAS criteria. There is a need for additional studies of the safety and efficiency of AS under conditions of Russian public health.

Одним из факторов, ограничивающих широкое принятие активного наблюдения (АН), является отсутствие консенсуса в отношении селекции пациентов. Исследована частота неблагоприятных гистологических находок, отдаленная общая и безрецидивная выживаемость у 152 пациентов, соответствующих критериям АН ERSPC (PRIAS) и перенесших позадилонную радикальную простатэктомию (РПЭ) в период с 1997 по 2010 г. Неблагоприятные гистологические характеристики выявлены у более 10 % пациентов, при медиане послеоперационного наблюдения 67 мес биохимический рецидив развился у 3 (2 %) пациентов. Пятии 10-летняя безрецидивная выживаемость составила 97 и 88,2 % соответственно. Гистологические и отдаленные онкологические результаты после РПЭ у пациентов, соответствующих критериям PRIAS, являются субоптимальными. Требуются дополнительные исследования, посвященные безопасности и эффективности применения АН в условиях отечественного здравоохранения.

prostate canceractive surveillanceradical prostatectomybiochemical recurrenceрак предстательной железыактивное наблюдениерадикальная простатэктомиябиохимический рецидив1. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481–8.Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481–8.2. Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.3. Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспер и клин урол 2011;2–3:6–7.Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспер и клин урол 2011;2–3:6–7.4. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.5. Cooperberg M.R., Carroll P.R., Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669–76.Cooperberg M.R., Carroll P.R., Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669–76.6. Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.7. Cooperberg M.R., Cowan J.E., Hilton J.F. et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011;29:228–34.Cooperberg M.R., Cowan J.E., Hilton J.F. et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011;29:228–34.8. Satkunasivam R., Kulkarni G.S., Zlotta A.R. et al. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 2013;190:91–6.Satkunasivam R., Kulkarni G.S., Zlotta A.R. et al. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 2013;190:91–6.9. van den Bergh R.C., Vasarainen H., van der Poel H.G. et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 2010;105:956–62.van den Bergh R.C., Vasarainen H., van der Poel H.G. et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 2010;105:956–62.10. Draisma G., Boer R., Otto S.J. et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.Draisma G., Boer R., Otto S.J. et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.11. Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.12. Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.13. van As N.J., Norman A.R., Thomas K. et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297–305.van As N.J., Norman A.R., Thomas K. et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297–305.14. Pinheiro L., Farinha R., Silva T. et al. Pathological features after radical prostatectomy for low risk prostate cancer candidates to active surveillance. Eur Urol Suppl 2007;6(2):279.Pinheiro L., Farinha R., Silva T. et al. Pathological features after radical prostatectomy for low risk prostate cancer candidates to active surveillance. Eur Urol Suppl 2007;6(2):279.15. Mitsuzuka K., Narita S., Koie T. et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int 2013;111(6):914–20.Mitsuzuka K., Narita S., Koie T. et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int 2013;111(6):914–20.16. Suardi N., Capitanio U., Briganti A. et al. Outcome of patients potentially suitable for active surveillance undergoing radical prostatectomy as first treatment choice. J Urol Suppl 2010;183(4):673.Suardi N., Capitanio U., Briganti A. et al. Outcome of patients potentially suitable for active surveillance undergoing radical prostatectomy as first treatment choice. J Urol Suppl 2010;183(4):673.17. Watts S.D., Leydon G., Ridout A.J. et al. The prevalence of depression and anxiety in men undergoing active surveillance for prostate cancer. Eur Urol Suppl 2013;12:275.Watts S.D., Leydon G., Ridout A.J. et al. The prevalence of depression and anxiety in men undergoing active surveillance for prostate cancer. Eur Urol Suppl 2013;12:275.18. Klotz L. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 2013;64:37–40.Klotz L. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 2013;64:37–40.19. Fujita K., Landis P., McNeil B.K. et al. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664–29.Fujita K., Landis P., McNeil B.K. et al. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664–29.20. Coffin G., Ploussard G., Cortesse A. et al. Does initial prostate functional MRI impact on treatment choice for patients on active surveillance? Eur Urol Suppl 2012;11:e765.Coffin G., Ploussard G., Cortesse A. et al. Does initial prostate functional MRI impact on treatment choice for patients on active surveillance? Eur Urol Suppl 2012;11:e765.